https://www.selleckchem.com/pr....oducts/netarsudil-ar
Conversely, a longer time from first allo-HCT to relapse (13·2 months) was associated with better OS (HR 0·50, 95% CI 0·37-0·69; P less then 0·0001). The results of the present analysis limit the ability to recommend one donor type over another when considering a second allo-HCT for relapsed AML. Our findings highlight that best OS is achieved when receiving the second allo-HCT in complete remission. To examine if sleep symptomatology was associated with subjective cognitive concerns or objective cognitive performance in
Beğen
Yorum Yap
Paylaş
